

# Anticancer medicine

*Bayer's successful acquisition of Schering gave a tremendous boost to Bayer HealthCare's research capabilities in the battle against cancer. The title story features reports on promising substances that are currently undergoing clinical testing, and takes a look at the new approaches being taken by the Bayer Schering Pharma Division. One hopeful candidate for cancer patients, for example, is the epothilone class of active substances, which in laboratory experiments cause tumor cells to burst. Bayer's cancer specialists are also targeting breast cancer and have developed a new anticancer substance as an alternative to the existing treatments. Finally, the essay on tumor stem cells describes how cancer treatment could change in the future.*

Cell division: the colored electron microscope image shows the reproduction of a breast cancer cell. At this stage, the chromosomes have already all been copied and transported into the daughter cell.



# Title story

Cancer research



29

Bayer research \_19

<b>Epothilones</b> <i>New active ingredient causes tumors to burst</i>	<b>32</b>	<b>RNA interference</b> <i>Anticancer drugs</i>	
<i>via gene research</i>	<b>38</b>	<b>Breast cancer</b> <i>Self-destruction program in the tumor</i>	<b>40</b>
<b>Cancer stem cells</b> <i>New prospects for tumor therapy</i>	<b>44</b>		